Results 51 to 60 of about 25,921 (246)
Pharmacokinetics and pharmacoepidemiology
, 1994 Pharmacokinetic methodology should be included in pharmacoepidemiology and postmarketing ...
J Zuidema, H G M Leufkens
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Background and Purpose Drug–drug interactions (DDIs) are associated with an increased risk of adverse drug reactions (ADRs). Hospitalized children are particularly vulnerable to DDIs and ADRs due to polypharmacy, frequent use of unlicensed or off‐label medications, and dosing regimens often extrapolated from adult data.
Emilie Laval +6 more
wiley +1 more source
, 2019 There is a need for research that provides an evidence base for the pharmacotherapy of people with mental disorders. The abundance of digital data in recent years has facilitated pharmacoepidemiology in the form of observational comparative effectiveness
Farooq
core +1 more source
British Journal of Clinical Pharmacology, EarlyView.Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le +5 more
wiley +1 more source
Paternal use of metformin and risk of major congenital malformations: A meta-analysis of 4 studies. [PDF]
Br J Clin PharmacolAbstract Metformin is the first‐line drug for the treatment of Type 2 diabetes. In 2022, a Danish registry‐based study reported a 40% increased risk of major congenital malformations following paternal exposure during spermatogenesis. This raised widespread concern about the use of metformin in males of reproductive age.
Damkier P +7 more
europepmc +2 more sources
British Journal of Clinical Pharmacology, EarlyView.Background Reporting adverse drug reactions (ADRs) is essential for drug safety. In Switzerland, healthcare professionals are legally required to report serious and unlabelled ADRs, yet under‐reporting remains widespread. We tested a novel method to increase reporting of ADR‐related hospitalizations.
Georgia Anita Weber +7 more
wiley +1 more source
Decoding RNA regulation: Challenges and opportunities for RNA‐based therapies in Europe
British Journal of Clinical Pharmacology, EarlyView.Abstract RNA‐based medicinal products represent a promising frontier in personalised medicine, offering sequence‐specific disease targeting at various molecular levels, yet their clinical translation in the European Union (EU) may be hindered by regulatory uncertainty around definitions and evidence requirements; this study therefore aims to identify ...
Olivia C. Lewis +4 more
wiley +1 more source
“My Addiction Doesn’t Define Me”—Experiences of Stigma among Mothers with Opioid Use Disorder
PharmacoepidemiologyOpioid use in women has increased by 300% since 1999, and opioid use disorder among pregnant women has quadrupled. The stigma of substance use disorder is a significant barrier to treatment, especially among women.
Christine Bakos-Block +4 more
doaj +1 more source
Pharmacoepidemiology, 2023 Background: Medicines information (MI) is a specialist area of pharmacy that provides evidence-based answers to often complex medication queries, utilising resources such as textbooks and databases.
Jeanie Misko, Matthew D. M. Rawlins
doaj +1 more source